DUBLIN, July 18, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.
Gland Pharma Ltd along with its partners MAIA Pharmaceuticals and Athenex Pharmaceutical Division (Athenex) announced the launch of a ready-to-use (RTU) bivalirudin injection in the United States of America. This is the first non-frozen ready-to-use bivalirudin 505b(2) NDA approved by the US Food and Drug Administration (FDA).
Hainan`s Generic Bivalirudin Receives Approval in US
Aurobindo Pharma Limited today said it got the approval of the US Food and Drug Administration (USFDA) to manufacture and market Bivalirudin injection of 250 mg/vial. In a press release here, Aurobindo Pharma LtdNSE -1.86 % said the drug was a generic equivalent to the Angiomax injection.
Aurobindo Pharma Ltd's Generic Bivalirudin Receives Approval In US
Mylan announced today the U.S. launch of its rivastigmine transdermal drug-delivery patch, a generic version of Novartis‘ (NYSE:NVS) Exelon therapy.
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.
Global pharmaceutical company Mylan has announced the US launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.
Mylan Institutional`s Generic Bivalirudin Receives Approval In US